

Company registration number: 695531

Dormul Bloodstock Ltd

Unaudited abridged financial statements

for the financial year ended 30th April 2025

Dormul Bloodstock Ltd

Contents

	Page
Balance sheet	1 - 2
Notes to the financial statements	3 - 5

Dormul Bloodstock Ltd

**Balance sheet
as at 30th April 2025**

	2025	2024
	€	€
Current assets	165,208	236,058
Creditors: amounts falling due within one year	<u>(233,330)</u>	<u>(274,644)</u>
Net current liabilities	<u>(68,122)</u>	<u>(38,586)</u>
Total assets less current liabilities	(68,122)	(38,586)
Accruals and deferred income	(71,230)	(63,730)
Net liabilities	<u><u>(139,352)</u></u>	<u><u>(102,316)</u></u>
Capital and reserves	<u><u>(139,352)</u></u>	<u><u>(102,316)</u></u>

The financial statements have been prepared in accordance with the Micro Companies Regime as permitted by section 280D of the Companies Act 2014.

We, as directors of Dormul Bloodstock Ltd state that:

- (a) the company is availing itself of the audit exemption (and the exemption shall be expressed to be "the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014"),
- (b) the company is availing itself of the exemption on the grounds that section 358 is complied with,
- (c) no notice under subsection (1) of section 334 has, in accordance with subsection (2) of that section, been served on the company,
- (d) the company qualifies for the Micro Companies Regime on the grounds that section 280D of the Companies Act 2014 is complied with and the financial statements have been prepared in accordance with the Micro Companies Regime,
- (e) the directors acknowledge the obligations of the company, under this Act, to -
 - (i) keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year, and
 - (ii) otherwise comply with the provisions of this Act relating to financial statements so far as they are applicable to the company,
- (f) the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a micro company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The notes on pages 3 to 5 form part of these abridged financial statements.

Dormul Bloodstock Ltd

**Balance sheet (continued)
as at 30th April 2025**

These abridged financial statements were approved by the board of directors on 14.01.26 and signed on behalf of the board by:

Peter Mulvany

Peter Mulvany (Jan 14, 2026 13:06:49 GMT)

**Peter Mulvany
Director**

Martin Doran

**Martin Doran
Director**

The notes on pages 3 to 5 form part of these abridged financial statements.

Dormul Bloodstock Ltd

Notes to the abridged financial statements Financial year ended 30th April 2025

1. General information

The company is a private company limited by shares, registered in Ireland (CRO registration number: 695531). The address of the registered office is Ballyfrory, Duncormick, Wexford.

2. Statement of compliance

These financial statements have been prepared in accordance with FRS 105, 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

3. Accounting policies and measurement bases

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 105 "The Financial Reporting Standard applicable to the Micro-entities Regime" issued by the Financial Reporting Council. The company qualifies as a micro company for the period, as defined by section 280D of the Companies Act 2014, in respect of the financial year and has applied the rules of the "Micro Companies Regime" in accordance with section 280E of the Companies Act 2014 and FRS 105.

The financial statements are presented in Euro, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied, net of discounts and Value Added Tax.

Sale of goods

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Taxation

Current tax is recognised for the amount of corporation tax payable in respect of the taxable profit for the current or past reporting periods using the tax rates and laws that have been enacted or substantively enacted by the reporting date.

Deferred tax is not recognised in respect of any timing differences.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

Financial instruments

The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Profit and Loss account.

Dormul Bloodstock Ltd

Notes to the abridged financial statements (continued)
Financial year ended 30th April 2025

Trade and other debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Creditors and accruals

Creditors and accruals are classified as current liabilities if payment is due within one year or less. If not they are presented as non-current liabilities. Trade payables are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Cash at bank and in hand

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice on not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Called-up share capital represents the nominal value of shares that have been issued. The share premium account includes any premiums received on issue of share capital. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

4. Appropriations of profit and loss account

	2025	2024
	€	€
At the start of the financial year	(102,416)	(52,259)
Loss for the financial year	(37,036)	(50,157)
At the end of the financial year	<u>(139,452)</u>	<u>(102,416)</u>

Dormul Bloodstock Ltd

Notes to the abridged financial statements (continued)
Financial year ended 30th April 2025

5. Directors transactions

During the financial year the company entered into the following arrangements relating to loans, quasi-loans and credit transactions:

	2025	2024
	€	€
At the start of the financial year	(270,000)	(208,950)
Advances made during the financial year	44,500	-
Amounts repaid during the financial year	-	(61,050)
At the end of the financial year	<u>(225,500)</u>	<u>(270,000)</u>

Disclosure for each director or other person is as follows:

Peter Mulvany

	2025	2024
	€	€
At the start of the financial year	(270,000)	(208,950)
Advances made during the financial year	44,500	-
Amounts repaid during the financial year	-	(61,050)
At the end of the financial year	<u>(225,500)</u>	<u>(270,000)</u>

6. Going concern

The company generated a loss for the current period of (€37,036) and it has negative reserves of (€139,352) at the year end. Therefore as at 30th April 2025 it would not be in a position to pay its debts if demanded for payment and is dependent on the continuing goodwill and support of its directors and creditors to continue operating as a going concern.

The financial statements do not include the adjustments that would result if the company was unable to continue as a going concern.

7. Post balance sheet events

No significant post balance sheet events took place after the financial year ended 30th April 2025.

8. Approval of financial statements

The board of directors approved these abridged financial statements for issue on . 14.01.26